Reishi Supplements UK — What the Evidence Says

What is Reishi?

Reishi is a woody, bracket-shaped mushroom native to temperate and tropical regions of Asia. Its scientific name is Ganoderma lucidum, and it belongs to the Ganodermataceae family. The mushroom typically grows on decaying hardwood trees and is recognised by its distinctive reddish-brown, lacquered cap.

In traditional Chinese and Japanese medicine, reishi has been used for centuries. It appears in classical texts under the names lingzhi (Chinese) and reishi (Japanese), where it was associated with longevity and vitality. It was historically reserved for royalty due to its rarity in the wild.

Today, reishi is cultivated commercially and widely used in the supplement industry. It is available in several forms: dried whole mushroom powder, hot-water extracts, alcohol extracts, dual extracts (combining both methods), and spore powder. Each form varies in its concentration of active compounds, which is relevant when comparing products. The mushroom is sometimes listed on labels as Ganoderma lucidum extract or reishi mushroom extract.

Key Active Compounds

Reishi contains several classes of bioactive compounds that researchers have studied and that Cogniscore looks for when assessing label transparency.

Beta-glucans are complex polysaccharides found in the cell walls of mushrooms. Research has examined beta-glucans from reishi in the context of immune-related outcomes. Because beta-glucan content varies considerably between products and extraction methods, Cogniscore treats a disclosed beta-glucan percentage as a key transparency marker.

Triterpenes, specifically ganoderic acids, are a group of compounds found almost exclusively in Ganoderma species. They require alcohol-based extraction to be captured effectively, which is why extraction method matters when evaluating a reishi product. Research has examined ganoderic acids in both in vitro and animal models.

Polysaccharides are a broader category that includes beta-glucans. General polysaccharide content is sometimes disclosed on labels as a proxy for overall extract quality, though it is a less specific marker than beta-glucan percentage alone.

Sterols and peptidoglycans are also present in reishi. These are less commonly disclosed on supplement labels and carry less weight in current scoring, though they form part of the full phytochemical profile researchers have investigated.

Benefit Areas Studied in Research

Immune support. Reishi is one of the most studied mushrooms in the context of immune function. Clinical trials and observational studies have used reishi extracts and spore powder to examine markers of immune activity in human subjects, including in oncology settings. Most human studies have used doses ranging from 1,000mg to over 5,000mg of dried mushroom equivalent per day, typically over periods of several weeks to months.

Stress resilience. Some research has examined reishi in the context of general stress and adaptogenic properties. The majority of this research comes from animal models and in vitro studies, with fewer large-scale human RCTs available. Researchers have looked at how reishi extracts interact with pathways associated with the stress response, though the human evidence base remains limited compared to some other adaptogens.

Fatigue. Human trials have studied reishi spore powder in specific patient populations, including individuals undergoing cancer treatment, to examine self-reported fatigue scores. A 2012 randomised controlled trial examined fatigue outcomes in breast cancer patients using a spore powder preparation. Research in healthy populations remains more limited.

Sleep quality. A smaller body of research has used reishi to examine sleep-related outcomes, including sleep latency and sleep duration. Some animal model studies have looked at reishi's interaction with sleep pathways. Human trial data in this area is limited, and most studies examining sleep have been short in duration or conducted in specific clinical populations rather than healthy adults.

The Science and Research

The research base for reishi spans in vitro work, animal models, and a modest number of human clinical trials. The quality and scope of studies varies considerably, and it is important to consider study type, population, and dose when reading any findings.

Tang et al. (2005), Annals of Oncology. This randomised, double-blind, placebo-controlled trial examined immune-related outcomes in cancer patients using a polysaccharide extract of Ganoderma lucidum. The trial used a dose of 1,800mg of extract per day over 12 weeks. Researchers measured markers of immune cell activity in the blood. This is one of the more rigorously designed human trials on reishi, though the population studied was a specific clinical group rather than healthy adults, which limits how broadly the findings can be applied.

Zhao et al. (2012), PLOS ONE. This randomised controlled trial examined cancer-related fatigue in breast cancer patients who had completed treatment. Participants received 3,000mg per day of Ganoderma lucidum spore powder over four weeks. Researchers used validated fatigue scales and quality-of-life questionnaires as outcome measures. The study was placebo-controlled and double-blind, which strengthens its design. Limitations include the specific patient population and the relatively short duration of four weeks.

Yuen and Gohel (2005), Immunopharmacology and Immunotoxicology. This was a review paper examining the existing body of research on anticancer properties of Ganoderma lucidum, drawing on in vitro and animal model studies. Review articles of this kind are useful for mapping the landscape of existing research but do not constitute direct human trial evidence. The authors noted that most mechanistic work at the time was preclinical.

Across the broader literature, reishi studies use a wide range of preparations, including hot-water extracts, alcohol extracts, whole dried powder, and spore powder. This variation makes it difficult to compare findings directly. Doses studied in human trials range from approximately 1,000mg to 5,400mg of dried mushroom equivalent per day, or 1.5g to 9g for extract preparations. Studies using doses outside this range, or using uncharacterised preparations, are harder to interpret. Most human trials have been conducted in clinical populations, and the evidence base in healthy adults is less developed.

How Cogniscore Evaluates Reishi

Cogniscore scores reishi-containing products on what brands publicly disclose, not on assumed quality. Dose is the first variable assessed. Human clinical trials have studied reishi at doses of 1,000mg to 5,400mg of dried mushroom equivalent per day. Products delivering less than 1,000mg per serving are below the dose range used in clinical research, and this is reflected in the score. Extract products are assessed against extract-specific trial doses, which range from 1.5g to 9g.

Source type and extraction method both affect scoring. Fruiting body preparations are more commonly used in clinical research and score higher than mycelium-only products, which can contain significant amounts of grain substrate. Dual extracts capture both water-soluble polysaccharides and alcohol-soluble triterpenes, and products that disclose this method score higher than those listing an unspecified extraction process. Beta-glucan percentage is one of the most important transparency markers for any mushroom supplement. Brands that disclose a verified beta-glucan figure, ideally supported by a certificate of analysis (COA), score higher than those that do not. A COA from an independent laboratory also contributes to the overall disclosure score. Read more in the full Cogniscore methodology.

Top Rated Products Containing Reishi

Ranked by Cogniscore — highest disclosure scores first. Scores reflect what brands publicly disclose, not product quality or efficacy.

Frequently Asked Questions